3-(4-甲氧基苯基)-1H-吲唑 | 55271-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-(4-甲氧基苯基)-1H-吲唑
• 英文名称: 3-(4-methoxyphenyl)-1H-indazole
• 英文别名: 6-methoxy-3-phenyl-1H-indazole；3-(4-methoxy-phenyl)-1(2)H-indazole；3-(4-Methoxy-phenyl)-1(2)H-indazol；3-(p-Methoxyphenyl)-indazole
• CAS: 55271-06-2
• 化学式: C₁₄H₁₂N₂O
• 分子量: 224.262
• InChiKey: TZXSAORFPSSAER-UHFFFAOYSA-N

物化性质

• 熔点：
  85-86 °C
• 沸点：
  436.4±28.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  3-(4-甲氧基苯基)-1H-吲唑 以88%的产率得到
  参考文献：
  名称：

  ADGER B. M.; BRADBURY S.; KEATING M.; REES C. W.; STORR R. C.; WILLIAMS M+, J. CHEM. SOC. PERKIN TRANS. , 1975, PART 1, NO 1, 31-40

  摘要：

  DOI：
• 作为产物：
  描述：

  苯甲亚胺酸乙酯 在 silver hexafluoroantimonate 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 copper diacetate 作用下， 以 乙醚 、 1,2-二氯乙烷 、 甲苯 为溶剂， 110.0~120.0 ℃ 、101.33 kPa 条件下， 反应 42.0h， 生成 3-(4-甲氧基苯基)-1H-吲唑
  参考文献：
  名称：

  Rh^III/Cu^II-Cocatalyzed Synthesis of 1H-Indazoles through C–H Amidation and N–N Bond Formation

  摘要：

  Substituted 1H-indazoles can be formed from readily available arylimidates and organo azides by Rh-III-catalyzed C-H activation/C-N bond formation and Cu-catalyzed N-N bond formation. For the first time the N-H-imidates are demonstrated to be good directing groups in C-H activation, also capable of undergoing intramolecular N-N bond formation. The process is scalable and green, with O-2 as the terminal oxidant and N-2 and H2O formed as byproducts. Moreover, the products could be transformed to diverse important derivatives.

  DOI：

  10.1021/ja4033555

文献信息

• Methods for treating an inflammatory condition or inhibiting JNK
  申请人：——

  公开号：US20040127536A1

  公开（公告）日：2004-07-01

  This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  这项发明通常涉及吲唑衍生物，具有以下结构： 1 或药用可接受的盐，其中R 1 ，R 2 和A如本文所述定义。这类化合物在治疗对JNK抑制剂有响应的广泛疾病和障碍，如炎症性疾病或障碍中具有用途。因此，还披露了治疗这些疾病和障碍的方法，以及包含一个或多个上述化合物的药物组合物。
• Indazole compounds, compositions thereof and methods of treatment therewith
  申请人：Bhagwat S. Shripad

  公开号：US20050009876A1

  公开（公告）日：2005-01-13

  This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

  这项发明通常涉及使用吲唑化合物来治疗或预防与蛋白激酶相关的疾病，包括酪氨酸激酶，诸如增殖性疾病、炎症性疾病、异常血管生成及其相关疾病、动脉硬化、黄斑变性、糖尿病、肥胖、疼痛等。这些方法包括向有需要的患者施用有效量的吲唑化合物，以抑制、调节或控制酪氨酸激酶信号转导。本文中提供了一种新型的吲唑化合物或其药用可接受的盐。
• A Synthesis of 1<i>H</i>-Indazoles via a Cu(OAc)₂-Catalyzed N–N Bond Formation
  作者：Cheng-yi Chen、Guangrong Tang、Fengxian He、Zhaobin Wang、Hailin Jing、Roger Faessler

  DOI：10.1021/acs.orglett.6b00611

  日期：2016.4.1

  facile synthesis of 1H-indazoles featuring a Cu(OAc)2-catalyzed N–N bond formation using oxygen as the terminal oxidant is described. The reaction of readily available 2-aminobenzonitriles with various organometallic reagents led to o-aminoaryl N–H ketimine species. The subsequent Cu(OAc)2-catalyzed N–N bond formation in DMSO under oxygen afforded a wide variety of 1H-indazoles in good to excellent

  描述了一种容易合成的1 H-吲唑，其特征在于使用氧作为末端氧化剂，形成Cu（OAc）2催化的N–N键形成。易于获得的2-氨基苯甲腈与各种有机金属试剂的反应产生了邻氨基芳基NH酮亚胺。随后在氧气下在DMSO中形成Cu（OAc）2催化的N–N键，从而以良好或极好的收率提供了多种1 H-吲唑。
• Indazole derivatives as JNK inhibitors and compositions and methods related thereto
  申请人：——

  公开号：US20020103229A1

  公开（公告）日：2002-08-01

  Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: 1 wherein R 1 , R 2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

  本发明公开了作为JNK选择性抑制剂的化合物。本发明的化合物是吲唑衍生物，具有以下结构： 1 其中R 1 ，R 2 和A如本文所述定义。此类化合物在治疗对JNK抑制产生响应的广泛病症方面具有用途。因此，还公开了治疗此类病症的方法，以及包含一个或多个上述化合物的药物组合物。
• ML212: A small-molecule probe for investigating fluconazole resistance mechanisms in <i>Candida albicans</i>
  作者：Willmen Youngsaye、Cathy L Hartland、Barbara J Morgan、Amal Ting、Partha P Nag、Benjamin Vincent、Carrie A Mosher、Joshua A Bittker、Sivaraman Dandapani、Michelle Palmer、Luke Whitesell、Susan Lindquist、Stuart L Schreiber、Benito Munoz

  DOI：10.3762/bjoc.9.171

  日期：——

  The National Institutes of Health Molecular Libraries and Probe Production Centers Network (NIH-MLPCN) screened >300,000 compounds to evaluate their ability to restore fluconazole susceptibility in resistant Candida albicans isolates. Additional counter screens were incorporated to remove substances inherently toxic to either mammalian or fungal cells. A substituted indazole possessing the desired bioactivity profile was selected for further development, and initial investigation of structure–activity relationships led to the discovery of ML212.

  国家卫生研究院分子图书馆和探针生产中心网络（NIH-MLPCN）筛选了超过300,000种化合物，以评估它们恢复对耐药念珠菌的氟康唑敏感性的能力。还加入了额外的对照筛选，以去除对哺乳动物或真菌细胞有毒的物质。选择了具有所需生物活性特征的取代吲唑化合物进行进一步开发，并初步研究结构-活性关系导致了ML212的发现。